Current guidance
4 items
Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Organic net sales growth | “8.3% to 9.3%” | for FY2026 | Company-defined | Jan 29, 2026 | 3 | Filing ↗ |
| Adjusted net earnings per diluted share | “$14.95 to $15.10” | for FY2026 | Company-defined | Jan 29, 2026 | 3 | Filing ↗ |
| Foreign exchange impact on sales and adjusted net earnings per diluted share | “slightly positive impact” | for FY2026 | Company-defined | Jan 29, 2026 | 1 | Filing ↗ |
| Sales pricing impact | “modestly favorable pricing impact” | for FY2026 | Company-defined | Jan 29, 2026 | 1 | Filing ↗ |
Adjusted net earnings per diluted share, for FY2025 — every statement across the year, each linked to its filing.
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|
| Net sales | — | — | 1 statement | — |
| Net sales impact from foreign exchange | — | 1 statement | — | — |
| Organic net sales growth | 3 statements | 4 statements | 1 statement | — |
| Adjusted net earnings per diluted share | 3 statements | 4 statements | 1 statement | 1 statement |
| Adjusted net earnings per diluted share impact from foreign exchange | — | 1 statement | — | — |
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 30, 2026 | FY2026 Q2 | 0000310764-26-000048 | 2 | Open filing ↗ |
| Apr 30, 2026 | FY2026 Q1 | 0000310764-26-000025 | 2 | Open filing ↗ |
| Jan 29, 2026 | FY2025 Q4 | 0000310764-26-000006 | 4 | Open filing ↗ |
| Oct 30, 2025 | FY2025 Q3 | 0000310764-25-000126 | 2 | Open filing ↗ |
| Jul 31, 2025 | FY2025 Q2 | 0000310764-25-000103 | 3 | Open filing ↗ |
| May 1, 2025 | FY2025 Q1 | 0000310764-25-000072 | 3 | Open filing ↗ |
| Jan 28, 2025 | FY2024 Q4 | 0000310764-25-000005 | 11 | Open filing ↗ |
| Oct 29, 2024 | FY2024 Q3 | 0000310764-24-000113 | 4 | Open filing ↗ |